Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Tipo de estudo
Tipo de documento
Intervalo de ano de publicação
1.
Neuroreport ; 11(6): 1351-5, 2000 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-10817620

RESUMO

Between 20 and 30% of AIDS patients have neurological symptoms characterized by motor impairment, memory loss and progressive dementia. Previous studies have implicated the HIV derived gp120, which produces behavioral deficits and electrophysiological alterations in rats. The goal of the present study was to describe the effect of this protein on the P3 event-related potential (ERP), evoked by a passive discrimination task in rats. We used II rats divided into two groups: HIV gp120 (n = 6) and control (n = 5). We recorded the P3 wave before any treatment (baseline), during the i.c.v. administration of either HIVgp 120 (700 ng/5 days) or saline (pH 7.2), and 24 h, 7, 14 and 21 days after the last injection. There were no changes between groups in the amplitude or latencies of the observed components (N1, P2, N2 and P3) evoked by target stimuli, during baseline or during the injection period. However, the HIV gp120 group showed a significant amplitude reduction in P3 wave 24 h after the last injection, while the N1, P2 and N2 waves remained unchanged. However, from the 7th day through the 21st day, P2 and N2 components also disappeared and only the N1 component could be observed in the HIV gp 20-treated group. These changes in the N2, P2 and P3 potentials, suggesting an alteration in cognitive processes, further support the neurotoxic activity of HIV gp120 and its role in AIDS dementia.


Assuntos
Complexo AIDS Demência/fisiopatologia , Aprendizagem por Discriminação/efeitos dos fármacos , Potenciais Evocados/efeitos dos fármacos , Proteína gp120 do Envelope de HIV/farmacologia , Complexo AIDS Demência/induzido quimicamente , Estimulação Acústica , Animais , Comportamento Animal/efeitos dos fármacos , Eletroencefalografia/efeitos dos fármacos , Potenciais Evocados/fisiologia , Potenciais Evocados Auditivos do Tronco Encefálico/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos
2.
Behav Brain Res ; 57(1): 1-7, 1993 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-8292248

RESUMO

It has been proposed that functions associated with the prefrontal cortex could change as a consequence of aging. Previous experiments in young rats have demonstrated that anatomical lesions or chronic GABA infusions into this area produce deficits in spatial delayed alternation tasks. The present study examines the effect of chronic (7 days) GABA or saline infusion into the prefrontal cortex on the performance of delayed alternation task in old rats (24 months). The results suggested that aged rats needed more sessions to acquire the delayed alternation task. GABA infusions into the prefrontal cortex produced deficits in spatial alternation tasks similar to those previously observed in young rats. Performance rapidly recovered after the infusion period. Histological analysis showed similar lesion size in both groups. The results suggest that aged prefrontal cortex and/or related areas participating in the acquisition of the delayed alternation task are more sensitive to aging processes. Furthermore, the prefrontal cortex is important for the retention of a previously learned spatial delayed alternation task. The structures involved in functional recovery from these deficits appear to be fully functional in aged rats.


Assuntos
Envelhecimento/efeitos dos fármacos , Aprendizagem por Discriminação/efeitos dos fármacos , Rememoração Mental/efeitos dos fármacos , Orientação/efeitos dos fármacos , Córtex Pré-Frontal/efeitos dos fármacos , Resolução de Problemas/efeitos dos fármacos , Ácido gama-Aminobutírico/farmacologia , Envelhecimento/fisiologia , Animais , Comportamento Apetitivo/efeitos dos fármacos , Comportamento Apetitivo/fisiologia , Atenção/efeitos dos fármacos , Atenção/fisiologia , Mapeamento Encefálico , Aprendizagem por Discriminação/fisiologia , Habituação Psicofisiológica/efeitos dos fármacos , Habituação Psicofisiológica/fisiologia , Bombas de Infusão Implantáveis , Masculino , Rememoração Mental/fisiologia , Orientação/fisiologia , Córtex Pré-Frontal/fisiologia , Resolução de Problemas/fisiologia , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Ácido gama-Aminobutírico/fisiologia
3.
Brain Res ; 913(1): 78-81, 2001 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-11532249

RESUMO

Approximately 35% of HIV-infected subjects, both children and adults, exhibit alterations in the sleep-waking cycle. HIV surface glycoprotein gp120 has been postulated to contribute to this abnormality. For example, it has been reported that HIVgp120 modifies sleep in freely-moving rats and that it also activates the ERK pathway in brain slices. The goal of this work was to determine if sleep changes induced by HIVgp120 in normal rats are mediated by the MAPK pathway. Our results show that a single intraventricular administration of HIVgp120 selectively increases REMS and that such an increase can be prevented by U0126, an inhibitor of ERK activating enzyme, MEK. In contrast, SB202190, a MAPK-p38 inhibitor, had no effect on HIVgp120-induced increase in REMS. These results suggest that HIVgp120 increases REMS in the rat by specifically affecting the ERK signal transduction pathway.


Assuntos
Complexo AIDS Demência/enzimologia , Encéfalo/enzimologia , Proteína gp120 do Envelope de HIV/farmacologia , Sistema de Sinalização das MAP Quinases/fisiologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Parassonias do Sono REM/enzimologia , Sono REM/fisiologia , Complexo AIDS Demência/fisiopatologia , Complexo AIDS Demência/virologia , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/virologia , Butadienos/farmacologia , Interações Medicamentosas/fisiologia , Inibidores Enzimáticos/farmacologia , Proteína gp120 do Envelope de HIV/metabolismo , Imidazóis/farmacologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Masculino , Quinases de Proteína Quinase Ativadas por Mitógeno/antagonistas & inibidores , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Nitrilas/farmacologia , Piridinas/farmacologia , Parassonias do Sono REM/induzido quimicamente , Parassonias do Sono REM/virologia , Ratos , Ratos Wistar , Sono REM/efeitos dos fármacos , Vigília/efeitos dos fármacos , Vigília/fisiologia , Proteínas Quinases p38 Ativadas por Mitógeno
4.
J Physiol Biochem ; 68(3): 411-20, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22351116

RESUMO

We determined in cultured kidney epithelial cells (LLC-PK(1)) the effects of high glucose, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) on mRNA and protein expression of the renal glucose transporters SGLT1 and SGLT2. Cultured monolayers were incubated with similar concentrations of IL-6 and TNF-α to those produced by LLC-PK(1) in the presence of 20 mM glucose. Confluent monolayers with either 5 (controls, C) or 20 mM glucose (high glucose, HG) were incubated in the presence of 5 mM glucose, 20 mM glucose, 10 pg/ml IL-6, or TNF-α alone or in combination. Separate groups with IL-6 and TNF-α were incubated with antibodies to their respective receptors. HG induced an increased SGLT1 mRNA at 48 h (p<0.05 vs. C) and protein expression in 120 h (p<0.05 vs. C). HG also induced an increased SGLT2 mRNA at 72 and 96 h (P<0.05 vs. C) and SGLT2 protein expression at 120 h (p<0.05 vs. C). In C, 10 pg/ml IL-6 or TNF-α did not modify SGLT1 mRNA (n.s vs. in the absence of cytokines). In contrast, cytokines induced an increased expression of SGLT1 protein at 120 h (p<0.05 vs. in the absence of cytokines), and SGLT2 mRNA and protein were increased at 96 and 120 h, respectively (p<0.05 vs. in absence of cytokines). No changes were observed when cells were incubated with cytokines and HG (n.s vs. C). In conclusion, this study showed that SGLT2 increased in the presence of IL-6 and TNF-α, indicating an autocrine modulation of the expression of this transporter by cytokines.


Assuntos
Interleucina-6/farmacologia , Transportador 2 de Glucose-Sódio/genética , Fator de Necrose Tumoral alfa/farmacologia , Animais , Células Cultivadas , Proteínas Facilitadoras de Transporte de Glucose/genética , Proteínas Facilitadoras de Transporte de Glucose/metabolismo , Interleucina-6/metabolismo , RNA Mensageiro/metabolismo , Transportador 1 de Glucose-Sódio/genética , Transportador 1 de Glucose-Sódio/metabolismo , Transportador 2 de Glucose-Sódio/metabolismo , Suínos/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
5.
Neurobiol Dis ; 7(4): 384-94, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10964609

RESUMO

Human immunodeficiency virus (HIV)-associated dementia (HAD) has been detected in 20-30% of patients suffering AIDS. The envelope glycoprotein 120 (gp120) derived from HIV seems to play a critical role in the pathophysiology of this dementia. Likewise, the feline immunodeficiency virus (FIV)-derived gp120 causes neurological and electrophysiological abnormalitites in cats. We have studied the effects of gp120 derived from HIV or FIV on learning and memory processing, hippocampal long-term potentiation (LTP), hippocampal neuronal cAMP production, the sleep-waking cycle, and locomotor activity and equilibrium in rats. Results showed that while both HIV- and FIV-gp120 impaired the rat's performance in the Barnes maze task, only HIVgp120 impaired the induction and maintenance of LTP. However, both glycoproteins induced a significant decrease in the posttetanic potentiation. HIVgp120 also caused a significant reduction in cAMP production in the hippocampus. Regarding the sleep-waking cycle, HIV- and FIV-gp120 increased the waking state and slow-wave sleep 1 (SWS1), while decreasing both SWS2 and REM sleep. Locomotor activity and equilibrium were significantly altered by these glycoproteins. These results suggest that HIVgp120 causes neurophysiological abnormalities and therefore may facilitate HAD development in AIDS patients.


Assuntos
Proteína gp120 do Envelope de HIV/farmacologia , Vírus da Imunodeficiência Felina/imunologia , Memória/efeitos dos fármacos , Sono/efeitos dos fármacos , Complexo AIDS Demência/fisiopatologia , Animais , Antígenos Virais/farmacologia , Gatos , Vírus da Imunodeficiência Felina/fisiologia , Potenciação de Longa Duração/efeitos dos fármacos , Potenciação de Longa Duração/fisiologia , Masculino , Memória/fisiologia , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Ratos , Ratos Wistar , Sono/fisiologia
8.
Salud pública Méx ; 23(6): 607-611, 1981.
Artigo em Espanhol | LILACS | ID: lil-11620

RESUMO

Se analizan los resultados obtenidos con la vacuna pertussis producida durante nueve anos en cultivo estacionario, utilizando las cepas 10536, 18334 y 18904 procedente de Michigan; y cinco anos en cultivo sumergido utilizando las cepas 509 y 134 procedentes de Holanda. Se logro un gran incremento de la produccion usando la fermentacion. La potencia de las vacunas fue determinada por el metodo de Kendrick (proteccion activa en el raton). El promedio de los resultados obtenidos fue de 13.75 UP/ml en cultivo estacionario y 10.51 UP/ml en cultivo por fermentacion.Aplicando la prueba de t se concluye que la diferencia de resultados es altamente significativa. Por otro lado y basandose en la dispersion de los resultados, puede afirmarse que con el metodo de fermentacion se obtiene menor variacion en la potencia de los lotes


Assuntos
Vacina contra Coqueluche , Meios de Cultura , Fermentação
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa